Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Key Stats

• Today's Range: $3.65 to $4.14
• 50-Day Range: $1.65 to $4.19
• 52-Week Range: $1.61 to $12.74
• Volume: 4.61 million shs
• Average Volume: 610,123 shs
• Market Capitalization: $151.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.67
• Consensus Rating: Moderate Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 43% of companies evaluated by MarketBeat, and ranked 547th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Metagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Metagenomi has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Metagenomi are expected to decrease in the coming year, from ($2.46) to ($2.52) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.45% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 38.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.45% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Metagenomi has recently decreased by 38.80%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

16 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.

MarketBeat Follows

15 people have added Metagenomi to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,900.00 in company stock.

MGX Stock Analysis - Frequently Asked Questions

How have MGX shares performed this year?

Metagenomi's stock was trading at $10.31 at the beginning of 2024. Since then, MGX shares have decreased by 60.7% and is now trading at $4.05.
View the best growth stocks for 2024 here.

When did Metagenomi IPO?

Metagenomi (MGX) raised $94 million in an initial public offering on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Who are Metagenomi's major shareholders?

Top institutional investors of Metagenomi include RA Capital Management L.P. (3.49%), PFM Health Sciences LP (2.76%), Geode Capital Management LLC (0.90%) and Jacobs Levy Equity Management Inc. (0.37%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick.
View institutional ownership trends.

How do I buy shares of Metagenomi?

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Metagenomi own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CUSIP: N/A
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 236
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.67
• High Stock Price Target: $25.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +311.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-68,250,000.00
• Net Margins: -134.27%
• Pretax Margin: -137.13%
• Return on Equity: -43.23%
• Return on Assets: -18.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.18
• Quick Ratio: 6.18

Sales & Book Value

• Annual Sales: $55.08 million
• Price / Sales: 2.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 37,424,000
• Free Float: N/A
• Market Cap: $151.57 million
• Optionable: N/A
• Beta: N/A